Trials / Not Yet Recruiting
Not Yet RecruitingNCT07103174
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
A Phase II Clinical Study on the Efficacy and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MG-K10 placebo | Administer the drug once every 4 weeks for a total of 6 times |
Timeline
- Start date
- 2025-08-16
- Primary completion
- 2027-07-16
- Completion
- 2027-12-16
- First posted
- 2025-08-05
- Last updated
- 2025-08-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07103174. Inclusion in this directory is not an endorsement.